RPR ZAGAM ONCE-DAILY EFFICACY IN COMMUNITY-ACQUIRED PNEUMONIA EQUIVALENT TO ERYTHROMYCIN AND CEFACLOR; FLUOROQUINOLONE LAUNCH SET FOR FIRST QUARTER 1997
Executive Summary
Zagam labeling contains data comparing the fluoroquinolone to erythromycin and cefaclor in community-acquired pneumonia, showing similar clinical success rates. Rhone-Poulenc Rorer's Zagam (sparfloxacin) gained approval on Dec. 19.